A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age
Conditions: Tuberculosis Interventions: Drug: EE/LNG; Drug: GSK3036656 Dose Level 1; Drug: GSK3036656 Dose Level 2 Sponsors: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Effects of Tuberculosis Infection on Development and Function of the Placenta
Conditions: Pregnancy Related; Tuberculosis Infection; Placenta Diseases Interventions: Other: TB infection Sponsors: Lund University; Addis Ababa University; Armauer Hansen Research Institute, Ethiopia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Mediastinal EBUS Cryobiopsy Study In Sweden
Conditions: Mediastinal Lymphadenopathy; Lung Cancer; Sarcoidosis; Lymphoma; Tuberculosis Interventions: Diagnostic Test: Mediastinal lymph nodes cryobiopsies Sponsors: Region Skane Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT
DiscussionPROSPECT aims to assess the safety and efficacy of a BDQ-containing SCR MDR-TB treatment at seventeen sites across China, while also providing high-quality data to guide SCRs administration under the direction of the China National Tuberculosis Program for MDR-TB. Additionally, PROSPECT will explore the potential benefits of extending the administration of the 9-month BDQ-containing SCR for participants without sputum conversion by week 16.Trial registrationClinicalTrials.gov NCT05306223. Prospectively registered on 16 March 2022 athttps://clinicaltrials.gov/ct2/show/NCT05306223?term=NCT05306223&draw=1&ra...
Source: Trials - April 1, 2024 Category: Research Source Type: clinical trials
Cali Sin Tos Aim 2
Conditions: Tuberculosis Interventions: Device: Chatbot; Diagnostic Test: Oral testing Sponsors: Yale University; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality
Conditions: All Cause Mortality; Cardiovascular Diseases; Invasive Cancer; Liver Cirrhosis; Type 2 Diabetes; Depression; Dementia; Injury Traumatic; Tuberculosis; Infections Interventions: Behavioral: Moderate Alcohol Drinking Pattern; Behavioral: Abstention Sponsors: Clinica Universidad de Navarra, Universidad de Navarra Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Princeton, N.J. and Tokyo, Japan– March 21, 2024– Otsuka Pharmaceutical Development& Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd., announce that interim data from a Phase 2b/c trial exploring... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
CAMBRIDGE, Mass., March 19, 2024. The Bill& Melinda Gates Medical Research Institute (Gates MRI) today announced that a Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine candidate is now underway, with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
Precision Rifampin Trial for Personalized Dosing
Conditions: Tuberculosis Interventions: Diagnostic Test: urine spectrophotometry for rifampin absorbance Sponsors: University of Virginia; Haydom Lutheran Hospital; Rutgers University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials
Precision Rifampin Trial
Conditions: Tuberculosis Interventions: Diagnostic Test: urine spectrophotometry for rifampin absorbance Sponsors: University of Virginia; Haydom Lutheran Hospital; Rutgers University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials
Systems Analysis and Improvement Approach to Prevent TB
Conditions: Tuberculosis; TPT; TB - Tuberculosis Interventions: Other: Systems Analysis and Improvement Approach for TB (SAIA-TB) Sponsors: Boston College; National Institutes of Health (NIH); Boston University; University of Washington; Medical Research Council, South Africa; National Institute of Nursing Research (NINR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Detection of Lipoarabinomannan in Urine Evaluation of the STANDARDTMF TBLAMFIA and Its Impact on the Initial TB Diagnosis
Conditions: Tuberculosis; Diagnoses Disease Interventions: Device: STANDARDTM F TB LAM FIA Sponsors: Ospedale San Raffaele Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial
ConclusionsOur application of estimands defined by the ICH E9 (R1) addendum offers a formalized framework for addressing the primary TB treatment trial objective and can promote uniformity in future trials by limiting heterogeneity in trial outcome definitions. We demonstrated the utility of our proposal using data from the REMoxTB randomized trial. We outlined methods for estimating each estimand and found consistent conclusions across estimands. We recommend future late-phase TB treatment trials to implement some or all of our estimands to promote rigorous outcome definitions and reduce variability between trials.Trial r...
Source: Trials - March 12, 2024 Category: Research Source Type: clinical trials
Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.
Conditions: Tuberculosis Interventions: Biological: 2.5 μg/ml EEC; Biological: 5μg/ml EEC; Biological: 5 unit（U） EC Sponsors: Chengdu CoenBiotech Co., Ltd; Beijing Chest Hospital, Capital Medical University; Wuhan Institute for Tuberculosis Control; The Public Health Clinical Center of Chengdu; Xuzhou Infectious Disease Hospital; Jiangsu Province Centers for Disease Control and Prevention; Changde First People ' s Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Correction: Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts
(Source: Trials)
Source: Trials - March 11, 2024 Category: Research Source Type: clinical trials
